Anakinra for the inflammatory complications of chronic granulomatous disease

Netherlands Journal of Medicine

Volumn 69, Issue 2, 2011, Pages 95-

  van de Veerdonk, F L ^a,b   Netea, M G ^a,b   Dinarello, C A ^b,c   van der Meer, J W M ^a,b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Nijmegen Institute for Infection Inflammation and Immunity N4i   (Netherlands)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLAMMASOME; INTERLEUKIN 1BETA; REACTIVE OXYGEN METABOLITE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

ADULT; CASE REPORT; CHRONIC GRANULOMATOUS DISEASE; CORTICOSTEROID THERAPY; EDITORIAL; GENE MUTATION; HUMAN; INJECTION SITE INFLAMMATION; INJECTION SITE PAIN; TREATMENT RESPONSE; UPREGULATION;

ADULT; ANTIRHEUMATIC AGENTS; GRANULOMATOUS DISEASE, CHRONIC; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; NADPH OXIDASE; REACTIVE OXYGEN SPECIES;

EID: 79952947988     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (4)

1. Seger RA. Chronic granulomatous disease: recent advances in pathophysiology and treatment. Neth J Med. 2010;68(11):334-340.
2. van de Veerdonk FL, Smeekens SP, Joosten LA, Kullberg BJ, Dinarello CA, van der Meer JW, et al. Reactive oxygen species-independent activation of the IL-1beta inflammasome in cells from patients with chronic granulomatous disease. Proc Natl Acad Sci U S A. 2010;107(7):3030-3033.
3. Granowitz EV, Porat R, Mier JW, Pribble JP, Stiles DM, Bloedow DC, et al. Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. Cytokine. 1992 Sep;4(5):353-360.
4. Bresnihan B. The safety and efficacy of interleukin-1 receptor antagonist in the treatment of rheumatoid arthritis. Semin Arthritis Rheum. 2001;30(5 Suppl 2):17-20.